A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Advanced Cancer
DRUG: LY3200882|DRUG: Pembrolizumab
Number of Participants with Dose Limiting Toxicity (DLT), Number of Participants with DLT, Up to 6 Weeks
Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR), ORR: Percentage of Participants with CR or PR, Baseline through Disease Progression or Death (Estimated at up to 12 Months)|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3200882 in Combination With Pembrolizumab, PK: Cmax of LY3200882 in Combination With Pembrolizumab, Baseline through Week 13|Duration of Response (DoR), DoR, Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated at up to 12 Months)
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.